Taisho Pharmaceutical Holdings Co., Ltd. (TAISF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Taisho Pharmaceutical Holdings Co., Ltd. (TAISF) Healthcare & Pipeline Overview

Taisho Pharmaceutical Holdings Co., Ltd., a Japanese multinational, develops, manufactures, and markets a diverse range of OTC and prescription drugs, with a strong presence in self-medication and prescription pharmaceutical segments, facing competition from both global and domestic players in the healthcare industry.

What Is the Investment Thesis for TAISF?

Taisho Pharmaceutical Holdings Co., Ltd. presents a mixed investment case. The company's established presence in the OTC drug market, particularly in Japan, provides a stable revenue base. The Prescription Pharmaceutical Operation Group offers growth potential through innovative drugs targeting various therapeutic areas. However, the company's P/E ratio of 37.0, coupled with a 6.3% profit margin, suggests a premium valuation. Key catalysts include successful clinical trials and regulatory approvals for pipeline drugs. Potential risks include increasing competition in the generic drug market and patent expirations on key products. Investors should closely monitor the company's ability to innovate and expand its product portfolio to sustain long-term growth.

Based on FMP financials and quantitative analysis

TAISF Key Highlights

• Operates through two main segments: Self-Medication Operation Group and Prescription Pharmaceutical Operation Group.
• Gross margin of 59.0% indicates strong pricing power and efficient cost management.
• P/E ratio of 37.0 suggests a premium valuation compared to some peers.
• Profit margin of 6.3% reflects profitability challenges amidst operating expenses.
• Beta of 0.50 indicates lower volatility compared to the overall market.

Who Are TAISF's Competitors?

TAISF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TAISF's Key Strengths?

• Strong brand recognition in Japan and other key markets.
• Diversified product portfolio across OTC and prescription drugs.
• Established distribution network and market access.
• Robust research and development capabilities.

What Are TAISF's Weaknesses?

• High dependence on the Japanese market.
• Exposure to generic competition and pricing pressures.
• Relatively low profit margin compared to some peers.
• Limited presence in some emerging markets.

What Could Drive TAISF Stock Higher?

• Clinical trial results for pipeline drugs targeting central nervous system disorders.
• Regulatory approvals for new OTC products in key international markets.
• Expansion of distribution network in emerging markets.
• Strategic partnerships with research institutions and pharmaceutical companies.

What Are the Key Risks for TAISF?

• Financial-distress signal — its Altman Z-Score of 1.77 sits in the distress zone (elevated bankruptcy risk).
• Rich valuation — a P/E of 37.0 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
• Increasing competition from generic drug manufacturers.
• Patent expirations on key products.
• Stringent regulatory requirements and compliance costs.
• Economic downturns and healthcare spending cuts.
• Fluctuations in currency exchange rates.

What Are the Growth Opportunities for TAISF?

• Expansion of OTC Product Line: Taisho Pharmaceutical can leverage its established brand and distribution network to expand its OTC product line in both domestic and international markets. The global OTC market is projected to reach $220 billion by 2027, presenting a significant opportunity for growth. Focus on developing innovative OTC products that address unmet consumer needs can drive revenue growth and market share.
• Development of Novel Prescription Drugs: The company's Prescription Pharmaceutical Operation Group has a pipeline of drugs under development targeting various therapeutic areas, including central nervous system, infectious, and metabolic diseases. Successful clinical trials and regulatory approvals for these drugs can drive significant revenue growth. The global prescription drug market is expected to reach $1.3 trillion by 2028, offering substantial potential for new drug launches.
• Strategic Acquisitions and Partnerships: Taisho Pharmaceutical can pursue strategic acquisitions and partnerships to expand its product portfolio, geographic reach, and technological capabilities. Acquiring companies with complementary products or technologies can accelerate growth and enhance competitiveness. Collaborating with research institutions and other pharmaceutical companies can facilitate the development of innovative therapies.
• Geographic Expansion in Emerging Markets: Expanding into emerging markets, such as Southeast Asia and Latin America, can provide new avenues for growth. These markets have a growing middle class and increasing healthcare spending, creating opportunities for both OTC and prescription drugs. Tailoring products and marketing strategies to local market needs is crucial for success.
• Focus on Personalized Medicine: As personalized medicine gains traction, Taisho Pharmaceutical can invest in developing targeted therapies and diagnostic tools. This approach involves tailoring treatments to individual patients based on their genetic makeup and other factors. Personalized medicine has the potential to improve treatment outcomes and reduce healthcare costs.

What Opportunities Does TAISF Have?

• Expansion into new geographic markets.
• Development of innovative prescription drugs.
• Strategic acquisitions and partnerships.
• Growth in the OTC market driven by self-medication trends.

What Threats Does TAISF Face?

• Increasing competition from generic drug manufacturers.
• Patent expirations on key products.
• Stringent regulatory requirements and compliance costs.
• Economic downturns and healthcare spending cuts.

What Are TAISF's Competitive Advantages?

• Established brand recognition and reputation, particularly in Japan.
• Strong distribution network and market access.
• Diverse product portfolio spanning OTC and prescription drugs.
• Research and development capabilities for creating new products.
• Intellectual property protection through patents and trademarks.

What Does TAISF Do?

Founded in 1912 and headquartered in Tokyo, Japan, Taisho Pharmaceutical Holdings Co., Ltd. has evolved into a prominent healthcare company with a global footprint. The company operates through two primary segments: Self-Medication Operation Group and Prescription Pharmaceutical Operation Group. The Self-Medication Operation Group focuses on over-the-counter (OTC) drugs, quasi-drugs, food products, and general medical supplies. Key products include the Lipovitan series of energy drinks, the Pabron series for cold remedies, and the RiUP series for hair re-growth. This segment also manages real estate leasing, facility management, and hotel operations. The Prescription Pharmaceutical Operation Group develops and markets ethical drugs, including treatments for osteoporosis, antibiotics, peripheral vasodilators, and type 2 diabetes. The company has a robust pipeline of products under development, targeting central nervous system, infectious, metabolic diseases, and orthopedic disorders. Taisho Pharmaceutical also supplies raw materials for pharmaceuticals and offers health foods and skincare products, demonstrating a diversified approach to healthcare.

What Products and Services Does TAISF Offer?

• Researches and develops over-the-counter (OTC) drugs.
• Manufactures and markets OTC drugs and prescription pharmaceutical products.
• Distributes and sells OTC drugs and prescription pharmaceutical products in Japan and internationally.
• Offers Lipovitan series of energy drinks.
• Provides Pabron series of cold remedies and sinus treatments.
• Develops RiUP series of hair re-growth treatment products.
• Offers ethical drugs, including Edirol for osteoporosis and Clarith, an antibiotic.
• Supplies health foods and skin care products.

How Does TAISF Make Money?

• Develops and manufactures OTC drugs and prescription pharmaceuticals.
• Markets and distributes products through various channels, including pharmacies, drug stores, and hospitals.
• Generates revenue from the sale of OTC drugs, prescription pharmaceuticals, and other healthcare products.
• Invests in research and development to create new products and improve existing ones.

What Industry Does TAISF Operate In?

Taisho Pharmaceutical operates in the competitive pharmaceutical industry, facing both global giants and domestic players. The industry is characterized by high R&D costs, stringent regulatory requirements, and increasing pressure on drug pricing. The global OTC market is expected to grow, driven by increasing self-medication trends and an aging population. The prescription pharmaceutical market is driven by innovation and the development of new therapies. Taisho Pharmaceutical's success depends on its ability to innovate, manage costs, and navigate the evolving regulatory landscape.

Who Are TAISF's Key Customers?

• Consumers seeking over-the-counter medications for common ailments.
• Patients requiring prescription drugs for various medical conditions.
• Healthcare professionals prescribing and recommending pharmaceutical products.
• Pharmacies and drug stores stocking and selling OTC and prescription drugs.

ROE 2%Key Financial Metrics

Return on equity for Taisho Pharmaceutical Holdings Co., Ltd. stands at 2.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.0%, showing how much profit it generates from its asset base. TAISF trades at a trailing price-to-earnings ratio of 37.03, above the Healthcare sector average of ~23x. Its free cash flow yield is -1.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.09 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.7%, the inverse of the P/E and a quick read on earnings relative to price.

How Taisho Pharmaceutical Holdings Co., Ltd. Is Valued

Relative to its peer group, TAISF's quantitative score of 50/100 is below the peer average of 62/100.

F-Score 6/9Financial Health

Taisho Pharmaceutical Holdings Co., Ltd.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.77 places it in the distress zone, a signal of elevated financial risk.

TAISF Financials

TAISF Latest News

No recent news available for TAISF.

TAISF Analyst Consensus

TAISF MoonshotScore

What Investors Ask About Taisho Pharmaceutical Holdings Co., Ltd. (TAISF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources